Poliomyelitis
Therapeutic area
Infectious Disease
Rare disease
Yes
- Definition
- An acute infectious disorder that affects the nervous system. It is caused by the poliovirus. The virus spreads by direct contact, and can be prevented by prophylaxis with the polio vaccine.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Poliomyelitis
- Therapeutic area
- Infectious Disease
- poliomyelitis
- Polia
- acute poliomyelitis
- polio
- poliomyelitis
- infantile paralysis
- Severity
- Severe
- Acquired
- Inflammatory
- Infectious Disease
- Neurology
- MONDO ID
- MONDO:0017373
- Parent condition
- MONDO:0002565
Related records
Broader conditions (27)
- Acquired motor neuron disease
- Acute disease
- Anterior horn disorder
- Central nervous system disorder
- Central nervous system infectious disorder
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Encephalomyelitis
- Enterovirus infectious disease
- Human disease
- Infectious disease
- Infectious disorder of the nervous system
- Inflammatory disease
- Motor neuron disorder
- Myelitis
- Nervous system disorder
- Neurodegenerative disease
Narrower conditions (6)
- Acute nonparalytic poliomyelitis
- Bulbar polio
- Bulbospinal polio
- Paralytic poliomyelitis
- Postpoliomyelitis syndrome
- Spinal polio
Trials (263)
- 3 Adjuvated Reduced Dose IPV-Al SSI and Non-adjuvated Full Dose IPV SSI Given as Primary Vaccinations to Infants
- A Campaign-based ID fIPV Administration Trial
- A Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated Poliomyelitis Vaccine in Healthy Infants
- A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a '1+2' Sequential Schedule With bOPV in Infants
- A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a "2+1"Sequential Schedule With bOPV in Infants
- A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV Vaccine
- A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates
- A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series
- A Post-marketing Safety Study of GSK Bio IPV Vaccine (PoliorixTM) in Korean Children
- A Safety Study of IMOVAX Polio Vaccine in Selected Cities in China
- A Safety Study of Sabin Inactivated Poliovirus Vaccine in Infants
- A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants
- A Study of Immunogenicity and Seroconversion With Sabin IPV Schedules in China.
- A Study of the Safety of IMOVAX Polio™ in China
- A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)
- A Study on Immunity Duration Against Polio Over 18 Months Infants After 2 or 3 Primary Doses Sabin IPV in China
- A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults
- A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV
- A Study to Evaluate Immunogenicity of Various Schedules of Inactivated Polio Vaccine
- A Study to Evaluate Pharyngeal Immunity to Poliovirus Type-2
Approved drugs (2)
- Hepatitis B virus hbsag surface protein antigen
- Norepinephrine bitartrate
Drugs in development (2)
- Poliovirus vaccine inactivated Phase 3
- Poliovirus vaccine live oral Phase 2
Other linked drugs (5)
- Bordetella pertussis filamentous hemagglutinin
- Bordetella pertussis pertactin autotransporter
- Diphtheria toxoid
- Tetanus toxoid
- Zinc sulfate